This is your opportunity to help lead the American Board of Audiology—the American Academy of Audiology’s committee dedicated to advancing the profession of audiology through audiology certification. In 2025, ABA introduced the Vestibular Audiology Specialty Certification and is currently developing a General Audiology Board Certification program for beta testing in fall 2026. In 2027, ABA will be conducting a practice analysis that will inform updates to existing exam blueprints and form the basis for additional certification programs in the future. We hope you share our enthusiasm and consider participating in this process that will positively impact the future of the ABA, the Academy and the audiology profession.
Open Board Positions
Three (3) seats available, each for a three-year term commencing October 1, 2026 through September 30, 2029.
Eligibility
You are eligible to apply if you are American Board of Audiology Certified, Board Certified in Pediatric Audiology, or Board Certified in Cochlear Implants for at least two full years in good standing and are an Academy member.
How to Apply
Complete the online application which should take about 10 minutes to complete. All nominations and accompanying materials are due no later than Monday, June 1, 2026.
| April 1 | Nominations Open |
| June 1 | Deadline to submit applications and accompanying materials |
| June 16 | ABA Board will select candidates to present to AAA |
| Mid-July | Candidates approved by AAA Board |
| October 1 | New ABA Board terms begin |
Recent Posts
Audiology CPT® Codes Enter Routine AMA RUC Review Process
Over the next several months, a significant number of CPT® codes used to report audiology function tests will undergo review through the AMA/Specialty Society Relative…
Academy Advocacy on Capitol Hill for Student Loan Reform and EHDI Support
Last week, Joanne Zurcher, MPP, and Academy member Melissa Heche, AuD, traveled to Capitol Hill to advocate for two important Academy priorities: protecting access to…
A New Era in Hearing Care: FDA Approves OTOF Gene Therapy
In the United States, mutations in the OTOF-gene (otoferlin gene) account for between one percent and eight percent of non-syndromic congenital hearing loss (Ford et…



